DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES – CII

/DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES – CII
DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES – CII2018-09-06T09:12:40+00:00

Prescription Drug Name:

DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES – CII

ID:

9fc8399c-25aa-492f-bc7b-596cbae4d39c

Code:

34391-3

DESCRIPTION:


id: dcdf6029-b647-4150-a3e8-b3f6f2e2ad52
displayName: DESCRIPTION SECTION
FDA Article Code: 34089-3

Dextroamphetamine sulfate is the dextro isomer of the compound d,l -amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methylphenethylamine, and is present in all forms of dextroamphetamine as the neutral sulfate. The structural formula is as follows:

(C9H13N)2 • H2SO4 Molecular Weight: 368.49

Each extended-release capsule is so prepared that an initial dose is released promptly and the remaining medication is released gradually over a prolonged period. Each capsule contains dextroamphetamine sulfate, and has the following inactive ingredients: colloidal silicon dioxide, dibutyl sebacate, ethylcellulose aqueous dispersion, methylcellulose, povidone, propylene glycol, sugar spheres and talc. The capsule shell ingredients in the 5 mg are D&C red no. 33, FD&C blue no. 1, FD&C yellow no. 6, gelatin, and titanium dioxide. The capsule shell ingredients in the 10 mg are black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The capsule shell ingredients in the 15 mg are black iron oxide, gelatin, red iron oxide, titanium dioxide, and yellow iron oxide. The imprinting ingredients are D&C yellow no. 10 aluminum lake, FD&C blue no. 1 aluminum lake, FD&C blue no. 2 aluminum lake, FD&C red no. 40 aluminum lake, pharmaceutical glaze, propylene glycol, and synthetic black iron oxide.

CLINICAL PHARMACOLOGY:


id: 2ea01872-115e-402a-98ed-8c2d3987e957
displayName: CLINICAL PHARMACOLOGY SECTION
FDA Article Code: 34090-1

Amphetamines are non-catecholamine, sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action. There is neither specific evidence which clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system. Dextroamphetamine sulfate extended-release capsules are formulated to release the active drug substance in vivo in a more gradual fashion than the standard formulation, as demonstrated by blood levels. The formulation has not been shown superior in effectiveness over the same dosage of the standard, non-controlled-release formulations given in divided doses.

INDICATIONS AND USAGE:


id: fc1c3c24-de3e-4718-bc05-65767e031a2a
displayName: INDICATIONS & USAGE SECTION
FDA Article Code: 34067-9

Dextroamphetamine sulfate is indicated: 1. In Narcolepsy. 2. In Attention Deficit Disorder with Hyperactivity, as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

CONTRAINDICATIONS:


id: 0b851f62-ea35-49f9-833b-356d53aad774
displayName: CONTRAINDICATIONS SECTION
FDA Article Code: 34070-3

Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. Agitated states. Patients with a history of drug abuse. During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).

WARNINGS:


id: 9147a958-79d1-47c1-b61e-f1900600a8c4
displayName: WARNINGS SECTION
FDA Article Code: 34071-1

Serious Cardiovascular Events Sudden Death in Patients with Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems: Children and Adolescents:  Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug. Adults:  Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see CONTRAINDICATIONS). Hypertension and Other Cardiovascular Conditions: Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see CONTRAINDICATIONS). Assessing Cardiovascular Status in Patients Being Treated With Stimulant Medications: Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g., electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation. Psychiatric Adverse Events Pre-Existing Psychosis: Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder. Bipolar Illness: Particular care should be taken in using stimulants to treat ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

DRUG ABUSE AND DEPENDENCE:


id: f458a669-015c-45ec-bf67-b6a88e9bcf1f
displayName: DRUG ABUSE AND DEPENDENCE SECTION
FDA Article Code: 42227-9

Dextroamphetamine sulfate is a Schedule II controlled substance. Amphetamines have been extensively abused. Tolerance, extreme psychological dependence and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. This is rare with oral amphetamines.

OVERDOSAGE:


id: 8757951f-6188-46a3-bf3c-fbfb2a14e0c9
displayName: OVERDOSAGE SECTION
FDA Article Code: 34088-5

Individual patient response to amphetamines varies widely. While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg; 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal. In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg. Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

DOSAGE AND ADMINISTRATION:


id: fb7019d4-2129-4d6f-a3b8-29ed4559a69a
displayName: DOSAGE & ADMINISTRATION SECTION
FDA Article Code: 34068-7

Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses – particularly with the extended-release capsule form – should be avoided because of the resulting insomnia.

HOW SUPPLIED:


id: ed7b0b5f-e43a-40fd-9d72-3864e5df5897
displayName: HOW SUPPLIED SECTION
FDA Article Code: 34069-5

Dextroamphetamine Sulfate Extended-Release Capsules are available as:10 mg: Brown opaque cap and colorless, clear body filled with white to off-white pellets. Imprinted in black ink barr 955. Available in bottles of:

Bottles of 20 NDC 54868-5479-1
Bottles of 60 NDC 54868-5479-0
15 mg: Dark brown opaque cap and colorless, clear body filled with white to off-white pellets. Imprinted in black ink barr 956. Available in bottles of:
Bottles of 10 NDC 54868-5388-0
Bottles of 30 NDC 54868-5388-1
Dispense in a tight, light-resistant container. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

MEDICATION GUIDE


id: 82e4ef28-ea78-4254-bb44-8fe6f7d2d59b
displayName: SPL MEDGUIDE SECTION
FDA Article Code: 42231-1

DEXTROAMPHETAMINE SULFATE EXTENDED-RELEASE CAPSULES – CII Read the Medication Guide that comes with Dextroamphetamine Sulfate Extended-Release Capsules before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about you or your child’s treatment with Dextroamphetamine Sulfate Extended-Release Capsules.

PRINCIPAL DISPLAY PANEL


id: b48bcf30-b64a-4908-a12a-c4caf703bb5c
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4

PRINCIPAL DISPLAY PANEL


id: 8ed9ab8c-6e7f-461d-adb6-e1e8dbf1ed8d
displayName: PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
FDA Article Code: 51945-4